JP2003128560A - Improving agent for blood fluidity - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide an improving agent for blood fluidity comprising proanthocyanidine in which the existence thereof is known in plants as an active ingredient. SOLUTION: Bloodstreams are improved by converting the proanthocyanidine, especially extracted from grape seeds into a dosage form such as a tablet, a capsule or a solution according to a known method and ingesting the resultant improving agent.

Description

Detailed Description of the Invention

[0001]

TECHNICAL FIELD The present invention relates to a blood flow improving agent containing proanthocyanidins as an active ingredient.

[0002]

BACKGROUND OF THE INVENTION In the human body, blood circulation plays an important role in supplying oxygen and nutrients and removing carbon dioxide and other metabolic waste products. These functions are essential for the activity and survival of tissue cells. In addition, biological defense and the function of the immune system also depend on this blood circulation.
As described above, the blood circulation is involved in many important ecological functions, and it has long been recognized that a healthy blood circulation is essential for maintaining human health. In addition, many reports have been made on the effects of foods ingested by daily meals on the heart and vascular system.

The fluidity of blood is unbalanced due to various factors such as smoking, hypertension, hyperlipidemia, diabetes and the like, and when this is progressed, blood is coagulated in blood vessels. As a result, when a thrombus is formed and the symptom progresses, a significant peripheral blood circulation disorder occurs, causing abnormal tissue. Therefore, maintenance of blood fluidity is essential for health.

The decrease in fluidity due to the increase in blood viscosity is governed by various factors, and the main ones are hematocrit, plasma composition and viscosity, red blood cell deformability, red blood cell aggregate formation, blood coagulation, red blood cell, and the like. Examples include aggregation of platelets. By changing these factors, it may be possible to improve blood flow at vascular bifurcations, reduce pressure at vascular stenosis, and improve blood fluidity at peripheral circulation sites such as cerebral blood vessels. .

[0005] In particular, in order that blood, which has a cell component of half its volume, behaves like a liquid, it largely depends on the deformability of red blood cells. The definition of red blood cell deformability is not always uniform, but it is understood to be the resistance of red blood cells to change their shape, or the mechanical adaptation of red blood cells to assume a new form (blood rheology). Recent progress, Medical Review, Inc., 14-56, 1992).

The effect of the deformability of red blood cells on blood fluidity is more directly important when the blood vessels are capillaries. The diameter of the capillaries varies depending on the tissue, but is about 5 μm on average. On the other hand, since the diameter of red blood cells (the shape of biconcave discs) is about 8 μm in humans, it is clear that red blood cells cannot pass through capillaries unless they are deformed. Therefore, the deformability of red blood cells is
It is the most important factor that affects the blood flow velocity and blood flow volume of capillaries.

Pentoxifylline and sarpogrelate are known as substances having an effect of improving the deformability of red blood cells, and drugs containing these as active ingredients are also clinically used. Of these, pentoxifylline is a drug that improves red blood cell fluidity in the microcirculation region by improving red blood cell metamorphosis, thereby improving blood fluidity.

SUMMARY OF THE INVENTION An object of the present invention is to provide a drug, food or drink which improves blood fluidity.

[0008]

In order to solve the above-mentioned problems, the present inventors have proposed a method of measuring blood flow using a groove serving as a model of a capillary on a silicon substrate surface as a flow path (Patent Publication No. 1).
As a result of extensive studies using 1-2285861), it was found that proanthocyanidins, in particular, proanthocyanidins obtained by extraction from grape fruit seeds, skins or squeezed lees, are effective in improving blood fluidity. The present invention has been completed. That is, the present invention is a blood fluidity improver containing proanthocyanidins as an active ingredient. Further, the present invention is a blood fluidity improver containing proanthocyanidin as an active ingredient, which is an extract obtained by extracting from grape fruit seeds, pericarp or squeezed lees.

The present invention will be specifically described below. The proanthocyanidin used in the present invention is a condensed tannin existing in various plants, that is, a group of compounds in which flavan-3-ol or flavan-3,4-diol as a constituent unit is bound by condensation or polymerization. Is given the name because it produces anthocyanidins such as cyanidin, delphinidin, and belargonidin by acid treatment. Therefore, the proanthocyanidins are dimers, trimers, and 4 of the above structural units.
High molecular procyanidins having a higher molecular weight than 10-mer,
All proanthocyanidins such as prodelphinidin and proberalgonidin and their stereoisomers are included.

Examples of plants containing proanthocyanidins include, for example, grape, adzuki bean, horse chestnut, pine, oak,
Examples include Willow willow and bayberry, which can be obtained by extraction from these plants by a known method, but proanthocyanidins extracted from grape fruit seeds, pericarp, or squeezed lees are particularly preferable.

Proanthocyanidins extracted from grape seeds are also commercially available, for example "Gravinol".
"Gravinol Super" (manufactured by Kikkoman Corporation)
Is mentioned.

The blood fluidity improver of the present invention contains the above-mentioned proanthocyanidin as an active ingredient, and its dosage form is a solid preparation such as tablets, granules, powders and capsules,
Alternatively, any form such as a liquid preparation such as an injection can be appropriately prepared by a known method. Binders, disintegrators, thickeners, dispersants, reabsorption promoters, corrigents, buffers, surfactants, solubilizers, preservatives, emulsifiers, isotonic agents usually used in these preparations. Agents, stabilizers, pH adjusters and excipients may be used as appropriate. In addition, it can be indirectly mixed with foods or food materials and used in the form of health foods.

The blood fluidity improving agent of the present invention comprises
Depending on the dosage form, age, weight, and indication of the patient, for example, in the case of injections, adult proanthocyanidins 0.25 to 250mg once a day, preferably about 5 to 40mg. Is for adults several times a day in a dose of about 2.5-2500 mg, preferably 50-
It is recommended to administer about 400 mg. Also, when ingested as a health food, the weight is 60 kg, and 50 to 400 per day
mg.

This blood flow improving agent is used as a therapeutic agent for abnormalities in blood fluidity caused by smoking, hypertension, hyperlipidemia, diabetes and the like, and is also used for prevention thereof. By taking and ingesting this blood flow improving agent, it can be expected to eliminate the cause of thrombus formation and prevent thrombus formation. Since the fluidity of blood is improved by doing so, it can be said that the present invention greatly contributes to human health.

The effects of the present invention will be described below with reference to experimental examples. Experimental Example 1 1. Panel Health 10 adults (7 men, 3 women, age 22-59)
Years old), a capsule containing proanthocyanidins (“Vinopower” manufactured by Kikkoman Corp., 200 mg of proanthocyanidins) with tap water (about 150 ml)
It was drunk at. In addition, in conducting the test, red wine,
The effects of large amounts of green tea, foods containing polyphenol, foods containing large amounts of vitamin C and vitamin E, soybean-related products, and the like and excessive drinking were excluded.

2. Blood collection was performed using a heparin-containing vacuum blood collection tube, and 5 ml each was collected before and 2 hours after drinking.

3. The collected blood is a cell microrheology measuring device (M
C-FAN, manufactured by Hitachi Haramachi Electronics Co., Ltd., was used according to the method of Kikuchi et al. (Microvasc. Res., 44, 226-240, 1992). That is, using heparin-collected whole blood, a microchannel array (Bloody 6-7, flow channel width 7 μm, Hitachi Haramachi Electronics Co., Ltd.) was used to flow with a water column difference of 20 cm, and a passage time of 100 μl of physiological saline was passed through the microchannel array. The passage time of 100 μl of blood when 12 seconds was determined.

4. Results These results are shown in Table 1. The blood passage time was calculated by Equation 1, and the improvement rate was calculated by Equation 2. Formula 1 Blood transit time = 100 μl blood transit time × 12 seconds / 100 μl physiological saline transit time Formula 2 Improvement rate (%) = {(pass time before drinking−pass time after drinking) / pass time before drinking} × 100

[0019]

[Table 1] Blood passage time (second / 100 μl) and improvement rate (%)

5. Among the 10 panelists who underwent the evaluation measurement, the whole blood transit time was extended in 2 of them, but the remaining 8 cells showed improvement in transit time. Particularly in Panel 10, the transit time of whole blood before drinking was slower than that of other panels, and a remarkable improving effect was observed. Blood passage time before drinking proanthocyanidins 57.
After 6 seconds, the blood flowed easily to 46.0 seconds after drinking, and the effect of improving blood flow was confirmed. In addition, a significant improvement was observed as compared with the case of drinking water, and it was confirmed that proanthocyanidin itself has a blood flow improving action.

Experimental Example 2 1. Panel experiment Panels are 10 healthy adults (9 males, 1 female, age 25-48 years old), and these panels contain proanthocyanidin-containing capsules ("Givynol Super" manufactured by Kikkoman Corp., about proanthocyanidins). (Containing 200 mg) was drunk for 1 week at lunch. In addition,
In conducting the test, the effects of a large intake of red wine, green tea, foods containing polyphenol, foods containing a large amount of vitamin C and vitamin E, soybean-related products, and the like and excessive drinking were excluded.

2. Blood collection was carried out by using a heparin-containing Terumo vacuum blood collection tube, 5 times each before drinking on the day of starting drinking, 7 days after drinking, and 4 hours after breakfast intake (around 11:00 am). After blood collection, 0.25 ml of heparin was added to 5 ml of blood in the vacuum blood collection tube.

3. Measurement The measurement was performed in exactly the same manner as the method described in Experimental Example 1 above.

4. Results These results are shown in Table 2. The blood passage time was obtained by the above-mentioned equation 1, and the improvement rate was obtained by the above-mentioned equation 2.

[0025]

[Table 2] Blood passage time (second / 100 μl) and improvement rate (%)

5. Evaluation It was recognized that drinking proanthocyanidins for one week tended to improve blood flow. In particular, the improving effect was remarkable for a person with poor blood flow before drinking (60 seconds or more). Also, when observing the flow of blood during blood flow measurement,
It was observed that platelet aggregation decreased after drinking. Therefore, it was shown that proanthocyanidins may improve blood flow by the action of improving red blood cell deformability and the action of inhibiting platelet aggregation.

Example 1 Tablets Tablets were prepared by the usual method with the following formulation.

Example 2 Capsule A capsule was prepared with the following composition. Gelatin and glycerin are used as the encapsulating material.

[0029]

INDUSTRIAL APPLICABILITY According to the present invention, proanthocyanidins have the effect of improving blood flow, and therefore can be used as a blood flow improving agent. By ingesting this compound daily, thrombus formation and the like can be prevented.

─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. ⁷ Identification code FI theme code (reference) // A23L 2/38 A23L 2/38 C 2/52 2/00 FF term (reference) 4B017 LC03 LG01 LP01 4B018 MD52 ME04 MF01 4C086 AA01 FA02 MA01 MA04 ZA36 ZA51 4C088 AB56 AC04 BA08 BA14 BA37 CA03 NA14 ZA36 ZA51

Claims (2)

[Claims] 1. A blood fluidity improver containing proanthocyanidins as an active ingredient. 2. The blood fluidity improver according to claim 1, wherein the proanthocyanidin is an extract obtained by extracting from grape fruit seeds, peels or squeezed lees.